Caption Management, LLC Acadia Pharmaceuticals Inc Call Options Transaction History

Caption Management, LLC

$5.74 Billion
Q3 2024

Call Options

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$15.14 - $19.14 $454,200 - $574,200	30,000 Added 100.0%	60,000 $923,000
Q2 2024 Aug 14, 2024	SELL	$14.62 - $18.42 $6.32 Million - $7.96 Million	-432,200 Reduced 93.51%	30,000 $487,000
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $7.78 Million - $13.5 Million	437,200 Added 1748.8%	462,200 $8.55 Million
Q4 2023 Feb 14, 2024	SELL	$20.78 - $31.77 $2.03 Million - $3.1 Million	-97,500 Reduced 79.59%	25,000 $782,000
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $1.98 Million - $3.18 Million	95,000 Added 345.45%	122,500 $2.55 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $489,500 - $705,375	27,500 New	27,500 $658,000
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $3.31 Million - $4.28 Million	-234,400 Reduced 83.89%	45,000 $738,000
Q2 2022 Aug 15, 2022	BUY	$13.01 - $27.22 $751,978 - $1.57 Million	57,800 Added 26.08%	279,400 $3.94 Million
Q1 2022 May 13, 2022	BUY	$20.94 - $27.5 $221,964 - $291,500	10,600 Added 5.02%	221,600 $5.37 Million
Q4 2021 Feb 11, 2022	BUY	$16.79 - $27.09 $3.24 Million - $5.22 Million	192,700 Added 1053.01%	211,000 $4.93 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $226,979 - $320,814	-11,700 Reduced 39.0%	18,300 $446,000
Q4 2020 Feb 16, 2021	BUY	$41.04 - $56.79 $1.23 Million - $1.7 Million	30,000 New	30,000 $1.6 Million
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $316,500 - $468,700	-10,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$22.22 - $44.01 $555,500 - $1.1 Million	-25,000 Reduced 71.43%	10,000 $359,000
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $565,950 - $958,300	35,000 New	35,000 $940,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.

Account